News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
690,415 Results
Type
Article (39950)
Company Profile (293)
Press Release (650172)
Section
Business (204374)
Career Advice (2026)
Deals (35423)
Drug Delivery (89)
Drug Development (81015)
Employer Resources (169)
FDA (16129)
Job Trends (14883)
News (345383)
Policy (32508)
Tag
Academia (2562)
Alliances (49340)
Alzheimer's disease (1277)
Approvals (16092)
Artificial intelligence (147)
Bankruptcy (355)
Best Places to Work (11639)
Biotechnology (207)
Breast cancer (190)
Cancer (1391)
Cardiovascular disease (110)
Career advice (1688)
Cell therapy (286)
Clinical research (64824)
Collaboration (490)
Compensation (271)
COVID-19 (2550)
C-suite (110)
Data (1396)
Diabetes (177)
Diagnostics (6175)
Earnings (84969)
Employer resources (147)
Events (110379)
Executive appointments (405)
FDA (16831)
Funding (444)
Gene therapy (199)
GLP-1 (604)
Government (4351)
Healthcare (18754)
Infectious disease (2643)
Inflammatory bowel disease (111)
Interviews (318)
IPO (16374)
Job creations (3647)
Job search strategy (1436)
Layoffs (422)
Legal (7878)
Lung cancer (201)
Manufacturing (208)
Medical device (13240)
Medtech (13245)
Mergers & acquisitions (19237)
Metabolic disorders (461)
Neuroscience (1610)
NextGen Class of 2024 (6534)
Non-profit (4486)
Northern California (1723)
Obesity (262)
Opinion (184)
Parkinson's disease (101)
Patents (122)
People (56650)
Phase I (20163)
Phase II (28548)
Phase III (21274)
Pipeline (516)
Postmarket research (2564)
Preclinical (8583)
Radiopharmaceuticals (236)
Rare diseases (266)
Real estate (5920)
Regulatory (21727)
Research institute (2334)
Resumes & cover letters (351)
Southern California (1477)
Startups (3588)
United States (15430)
Vaccines (564)
Weight loss (182)
Date
Last 7 days (172)
Last 30 days (1610)
Last 365 days (34615)
2025 (92)
2024 (35352)
2023 (40181)
2022 (51265)
2021 (55818)
2020 (54190)
2019 (46647)
2018 (35130)
2017 (32199)
2016 (31620)
2015 (37692)
2014 (31466)
2013 (26494)
2012 (28684)
2011 (29384)
2010 (27420)
Location
Africa (722)
Arizona (198)
Asia (37460)
Australia (6131)
California (3878)
Canada (1474)
China (323)
Colorado (173)
Connecticut (180)
Europe (80369)
Florida (550)
Georgia (136)
Illinois (395)
Indiana (228)
Maryland (640)
Massachusetts (3014)
Michigan (175)
Minnesota (296)
New Jersey (1125)
New York (1107)
North Carolina (748)
Northern California (1723)
Ohio (148)
Pennsylvania (941)
South America (1096)
Southern California (1477)
Texas (561)
Utah (108)
Washington State (404)
690,415 Results for "gate neurosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gate Neurosciences and University of Pittsburgh Collaborate to Initiate Phase 2 Trial Combining Apimostinel with Digital Therapeutic for Depression
December 3, 2024
·
3 min read
Press Releases
Gate Neurosciences Presents New Data and Insights Highlighting Unique Pharmacology of Synaptic Function Modulators at the 2024 ACNP Annual Meeting
December 12, 2024
·
5 min read
Gate Neurosciences to Share New Data and Research Insights on its Synaptic Function Molecules with Multiple Posters at 2024 ASCP Annual Meeting
Gate Neurosciences today announced upcoming activities at the 2024 annual meeting of the American Society of Clinical Psychopharmacology (ASCP), being held in Miami Beach, FL, from May 28-31, 2024.
May 15, 2024
·
4 min read
Business
Gate Neurosciences Announces Clinical Collaboration with Beacon Biosignals to Advance Precision EEG Biomarkers in Major Depressive Disorder
Gate Neurosciences today announced a strategic collaboration with Beacon Biosignals to further advance the use of electroencephalogram (EEG) biomarkers across the company’s clinical pipeline in neuropsychiatry and cognition.
January 24, 2024
·
4 min read
Drug Development
Gate Neurosciences Announces Positive Topline Human EEG Biomarker Results Demonstrating Dose-Dependent Target Activation in Phase 1 Study of Apimostinel
Gate Neurosciences, a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced positive topline qEEG biomarker and safety results from its Phase 1 multiple ascending dose study of apimostinel in healthy volunteers.
November 7, 2023
·
4 min read
BioMidwest
Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels
Adolore BioTherapeutics announced the publication of its manuscript titled, " rdHSV-CA8 non-opioid analgesic gene therapy decreases somatosensory neuronal excitability by activating Kv7 voltage-gated potassium channels,[1]” in the peer-reviewed journal, Frontiers in Molecular Neuroscience.
May 16, 2024
·
6 min read
Press Releases
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
December 4, 2024
·
3 min read
Business
Dr. Patrice Matchaba Appointed as Chief Executive Officer of the Bill & Melinda Gates Medical Research Institute
The Bill & Melinda Gates Medical Research Institute announced the appointment of Patrice Matchaba, MD, as Chief Executive Officer, starting June 10, 2024.
May 28, 2024
·
3 min read
Press Releases
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
December 3, 2024
·
4 min read
Press Releases
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML
December 2, 2024
·
13 min read
1 of 69,042
Next
